Desensitization in kidney transplantation: Review
Open Access
- 27 December 2021
- journal article
- Published by JSC National Scientific Medical Research Center in Journal of Clinical Medicine of Kazakhstan
- Vol. 18 (6) , 32-34
Abstract
Sensitization to human leukocyte antigens (HLA) antigens is the main obstacle to getting the kidney either from a living or deceased donor. HLA sensitization occurs as the result of repeated pregnancy, blood transfusion, or previous transplantation. Overcoming the HLA incompatibility is one of the approaches to decrease the organ shortage. There are 3.5 % highly sensitized patients among 3012 patients on the waiting list for kidney transplantation in Kazakhstan. In this review, we have discussed most common approaches of desensitization for HS kidney recipients. Huge progress has been made in the field of desensitization in transplant medicine worldwide. We suppose, that implementation the desensitization protocols in clinical guidelines will improve patient survival and outcome after kidney transplantation.Keywords
This publication has 20 references indexed in Scilit:
- Survival Benefit with Kidney Transplants from HLA-Incompatible Live DonorsNew England Journal of Medicine, 2016
- A Phased Desensitization Protocol With Rituximab and Bortezomib for Highly Sensitized Kidney Transplant CandidatesTransplantation Direct, 2015
- A Systematic Review of the Use of Rituximab for Desensitization in Renal TransplantationTransplantation, 2014
- Quantifying the Risk of Incompatible Kidney Transplantation: A Multicenter StudyAmerican Journal of Transplantation, 2014
- Desensitization in HLA-Incompatible Kidney Recipients and SurvivalNew England Journal of Medicine, 2011
- Desensitization Protocols and Their OutcomeClinical Journal of the American Society of Nephrology, 2011
- Rituximab and Intravenous Immune Globulin for Desensitization during Renal TransplantationNew England Journal of Medicine, 2008
- IVIG and HLA Antibodies. Evidence for Inhibition of Complement Activation but Not for Anti‐Idiotypic ActivityAmerican Journal of Transplantation, 2005
- Clinical uses of intravenous immunoglobulinClinical and Experimental Immunology, 2005
- Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior TherapyThe Oncologist, 2003